Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. [Yahoo! Finance]
Celularity Inc. - Class A (CELU)
Company Research
Source: Yahoo! Finance
“Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 were in excess of $24 million, which is greater than our full year sales in 2023,” said Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder of Celularity. “We expect Rebound sales to contribute meaningfully in the fourth quarter 2024 and to fulfill expected full year 2024 biomaterial sales which we announced in February, augmenting our other revenues from biobanking and research agreements,” added Dr. Hariri. “I am very pleased with Celularity's commercial traction and optimistic about our future performance.” Rebound complements Celularity's existing portfolio of advanced biomaterials, which includes innovative placental-derived products that have shown strong market demand. The addition of Rebound enhances Celularity's ability to address a broader patient population in wound care and soft tissue repair. By leveraging the unique properties of placen
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificGlobeNewswire
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter [Yahoo! Finance]Yahoo! Finance
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterGlobeNewswire
- Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 MillionGlobeNewswire
- Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelGlobeNewswire
CELU
Earnings
- 1/2/24 - Miss
CELU
Sec Filings
- 11/19/24 - Form DEF
- 11/15/24 - Form NT
- 11/8/24 - Form 8-K
- CELU's page on the SEC website